Physicians Urge Protection for Cancer Care in New IfPA White Paper
Once upon a time, the gravity of cancer ensured its patients access to life-saving treatments.
Exchange Plans Disrupt Rx Access for Rare Disease Patients, New Study Reveals
New research suggests that rare disease patients purchasing health coverage through a state or federal exchange face an all-too-common challenge: access to so-called orphan drugs.
Health Care Partnership Could Help Access to Real World Data
Real world data could improve patient care and result in more targeted pharmaceutical innovation, a new Morning Consult blog post suggests.
Webinar Features States’ Fights against Discriminatory Cost-sharing
As concerns about insurers’ discriminatory practices against chronic disease patients grow, several states have taken steps to limit coverage models that require excessive cost-sharing.
Online Health Resources Bolster Physician-Patient Relationship
Physicians know that having informed patients can help maximize the physician-patient relationship.
Innovation Goes Interactive with New Data Hub
Infographics, slide shows and interactive timelines now bring the latest information on emerging medical therapies together in one place: PhRMA’s new Innovation Hub.
IfPA Urges Caution in New “Indication Extrapolation” Policy Brief
The Food and Drug Administration’s approval process ensures safety and efficacy for each medical therapy and each indication approved.
New AfPA Video Examines Pain Management Policy
How can policy limit prescription pain pill abuse without impeding medical access for patients with legitimate pain?
Rare Disorders Organization Stresses Testing, Transparency on Biosimilars
Maximizing biologic medicine’s potential for rare disease patients means observing needed safety precautions.
Hydrocodone Reclassification Alters Pain Treatment Rules
In the newest move to reduce prescription opioid abuse, the U.S. Drug Enforcement Administration has reassigned hydrocodone combination products (HCPs) to Controlled Substance Schedule II.
